Caledonia is an exploration, development and mining company focused on Southern Africa. Caledonia's primary asset is a 49% interest in the Blanket Mine in Zimbabwe which produced over 45,500 ounces of gold in 2013 at a cash cost of US$613/oz.Caledonia has a strong, experienced management team and Board of Directors with diverse expertise in gold production, exploration, mine development, finance and marketing.

Aus­tralian Secu­ri­ties Exchange listed Scot­gold Resources Lim­ited (ASX:SGZ) was estab­lished in 2007 and listed on the ASX in Jan­u­ary 2008. The company’s shares were admit­ted to trad­ing on the AIM mar­ket of the Lon­don Stock Exchange (AIM:SGZ) in Feb­ru­ary 2010. The Company’s prin­ci­pal objec­tive, since 2008, has been the advance­ment of the Conon­ish Gold and Sil­ver Project in Scotland’s Grampian High­lands to a pro­duc­tion deci­sion and explo­ration of the highly prospec­tive ten­e­ments com­pris­ing the Grampian Gold Project with the view of iden­ti­fy­ing fur­ther project opportunities.

Introducing Solo Oil

- Oil and gas Investment company- Listed on the London AiM Market (SOLO)

Objectives

To acquire and develop a diverse global portfolio of oil & gas assets

Portfolio

Non-operated oil & gas assets:

- Major stake in the prolific Ruvuma Basin, Tanzania- Interest in Kiliwani North (KNDL), Tanzania- More than 5 tcf of prospective resources identified in Tanzania- Ntorya-1 (Tanzania) discovery flowed 20 mmscfd and 139 bopd- Participation in UK Weald Basin exploration projects, including Horse Hill- Strategic investment in Burj Africa, West Africa- Enhanced Oil Recovery project in Ontario, Canada

Sound Energy is a well-funded Mediterranean upstream company, listed on AIM, with cost covering production, a cornerstone investor, a strategic partnership with Schlumberger (one of the largest companies in our sector) and an active and potentially transformational drill programme.

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.